INTRAPARTUM FETAL PH MONITORING IN THE PREMATURE FETUS.

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$50,000.00
Award Year:
1988
Program:
SBIR
Phase:
Phase I
Contract:
n/a
Agency Tracking Number:
7954
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
International Biomedics Inc
1631 220th Ave Se, Bothell, WA, 98021
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
() -
Business Contact:
() -
Research Institution:
n/a
Abstract
FETAL BLOOD PH IS VALUABLE FOR HIGH-RISK CARE. CLINICAL EVALUATION OF OUR PATENTED CONTINUOUS INTRAPARTUM FETAL SCALP TISSUE PH/ECG PROBE (OBPH PROBE) DEMONSTRATED PH CAN BE MONITORED BY OUR PROBE IN THE TERM FETUS. OUR AIM ISTO OFFER OBPH PROBES DESIGNED FOR THE PRETERM FETUS AND FOR THE FETUS WITH A VERY HAIRY SCALP. (HAIR HINDERS SEATING OF THE PROBE). THE DIMENSIONS OF THE CURRENT OBPH PROBE'S SPIRAL RELATE TO THE PI'S STUDY OF INTRAPARTUM PELVIMETRY X-RAYS IN TERM PREGNANCIES. (HOCHBERG, 1981) NO OTHER RELEVANT LITERATURE WAS FOUND. ACCORDINGLY, DURING PHASE I WE WILL GATHER, TABULATE AND ANALYZE THE FETAL ANATOMIC AND CLINICAL DATA NEEDED TO DESIGN SAFE NEW OBPH PROBES. AND, WE WILL DEVELOPCLINICAL CRITERIA FOR PROBE SELECTION. INVESTIGATORS WILL USE INTRAVAGINAL ULTRASOUND IMAGING FOR FETAL SCALP THICKNESS (FST) MEASURES AND THEY WILL PROVIDE RELEVANT CLINICAL DATA. PROBES WILL BE DESIGNED AND BENCH TESTED. PHASE II WILL INCLUDE FDA/IDE CONTROLLED CLINICAL TRIALS.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government